BioSpace News Archive

Genetown

Ginkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Ginkgo Bioworks announced its participation in the 27th American Society of Gene & Cell Therapy Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics.

May 6, 2024
·
6 min read
Drug Development

Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas Therapeutics AB announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck.

May 6, 2024
·
7 min read
Biotech Bay

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia

Boehringer Ingelheim presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia .

May 6, 2024
·
6 min read
Drug Development

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

ADC Therapeutics SA announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® demonstrated a high response rate in patients with relapsed/refractory marginal zone lymphoma.

May 6, 2024
·
8 min read
Drug Development

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics, Inc., a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, announced topline results from its Phase 3 global pivotal study of uproleselan in 388 patients with R/R AML.

May 6, 2024
·
6 min read
Business

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

ADC Therapeutics SA reported financial results for the first quarter ended March 31, 2024, and provided business updates.

May 6, 2024
·
22 min read
Business

BIOLASE to Report First Quarter 2024 Results on May 13, 2024

BIOLASE, Inc. announced that it will release first quarter 2024 financial and operating results on Monday, May 13, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.

May 6, 2024
·
2 min read
Genetown

Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring) A Study of AC5® Advanced Wound System in Patients with Lower Extremity Wounds to be Featured in a Clinical Poster

Arch Therapeutics, Inc. announced that the Company’s first commercial product, AC5® Advanced Wound System, will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting, which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.

May 6, 2024
·
5 min read
Business

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Voyager Therapeutics, Inc., a biotechnology company dedicated to advancing neurogenetic medicines, announced it will report first quarter 2024 financial and operating results after market close on Monday, May 13, 2024.

May 6, 2024
·
1 min read
Business

Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Omega Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2024, and highlighted recent Company progress.

May 6, 2024
·
10 min read